Cantor Fitzgerald analyst Charles Duncan lowered the firm’s price target on Marinus Pharmaceuticals (MRNS) to $4 from $13 and keeps an ...

RBC Capital lowered the firm’s price target on Marinus Pharmaceuticals (MRNS) to $1 from $3 and keeps a Sector Perform rating on the ...

Fintel reports that on October 25, 2024, TD Cowen downgraded their outlook for Marinus Pharmaceuticals (NasdaqGM:MRNS) from ...

The growth of the DEE treatment market can be attributed to the increasing prevalence of developmental and epileptic ...

The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a ...

Marinus Pharmaceuticals (MRNS) stock was downgraded at TD Cowen and Truist after a Phase 3 failure for lead asset, ganaxolone ...

Marinus Pharmaceuticals has reported that the Phase III TrustTSC trial of oral ganaxolone in treating seizures linked to ...

Marinus said it will discontinue development of the drug, ganaxolone, and take further steps to reduce costs, including job ...

Ganaxolone is a neuroactive steroid GABAA receptor positive modulator that targets the brain’s anti-seizure response.

On Thursday, Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) stock plunged after the company revealed disappointing data from the ...

The recent trial flop for Ztalmy, this time in tuberous sclerosis complex (TSC)-associated seizures, leaves the company in a ...